Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.42 |
| ▸ | KMO | O15229 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.37 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.36 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759587 | 0.84 | AAK1 (0.38) | AAK1SORT1KMOTACR1KDM4E | |
| SCHEMBL7411662 | 0.81 | NOTUM (0.42) | AAK1SORT1TACR1KDM4EHTT | |
| SCHEMBL1699267 | 0.80 | NAPRT (0.43) | SORT1KMOASPHKDM4EKDM8 | |
| SCHEMBL14907699 | 0.79 | KMO (0.41) | SORT1KMOASPHKDM4EKDM8 | |
| SCHEMBL30613704 | 0.79 | KMO (0.43) | SORT1KMOASPHKDM4EKDM8 | |
| SCHEMBL15880100 | 0.79 | HSD17B10 (0.43) | SORT1KMOASPHKDM4EKDM8 | |
| SCHEMBL3540937 | 0.79 | KMO (0.43) | SORT1KMOASPHKDM4EKDM8 | |
| SCHEMBL23012638 | 0.78 | SLC22A12 (0.39) | AAK1SORT1KMOASPH | |
| SCHEMBL31214548 | 0.78 | MAPT (0.40) | SORT1KMODHODHHDAC6ASPH | |
| SCHEMBL29488309 | 0.78 | SLC22A12 (0.39) | AAK1SORT1KMOASPH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114349694-B | Synthetic method of 4-trifluoromethyl nicotinic acid | 淮北龙溪生物科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20220289685-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-09-15 | — | — | US | disclosed |
| EP-4017591-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-29 | — | — | EP | disclosed |
| CN-114206856-A | Anti-malarial hexahydropyrimidine analogues | UCB生物制药有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021032687-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | WO | disclosed |
| US-8481749-B2 | N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides and their use as herbicides | BAYER CROPSCIENCE AG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20120058892-A1 | N-(TETRAZOL-5-YL)- AND N-(TRIAZOL-5-YL)ARYLCARBOXAMIDES AND THEIR USE AS HERBICIDES | BAYER CROPSCIENCE AG (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058892-A1 | N-(TETRAZOL-5-YL)- AND N-(TRIAZOL-5-YL)ARYLCARBOXAMIDES AND THEIR USE AS HERBICIDES | ZYX, NAT1, CYCS | AAK1 2457/4885SORT1 4846/4885KMO 277/4885 |
| US-20220289685-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | G6PD, DPYD, DHFR | AAK1 2957/4885SORT1 4203/4885KMO 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.